Plumbagin inhibits invasion and migration of liver cancer HepG2 cells by decreasing productions of matrix metalloproteinase-2 and urokinase-plasminogen activator

Hepatology Research

Volumn 39, Issue 10, 2009, Pages 998-1009

  Shih, Yuan Wei ^a   Lee, Yi Chieh ^a   Wu, Pei Fen ^b   Lee, Yuan Bing ^c   Chiang, Tai An ^d  

^a Institute of Biomedical Engineering   (Taiwan)

^b TAJEN UNIVERSITY   (Taiwan)

^c Yongkang Veterans Hospital   (Taiwan)

^d CHUNG HWA UNIVERSITY OF MEDICAL TECHNOLOGY   (Taiwan)

Author keywords

Invasion; Matrix metalloproteinase 2; Migration; Plumbagin; Urokinase plasminogen activator

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CASEIN; GELATIN; GELATINASE A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLUMBAGIN; PROTEIN C FOS; PROTEIN C JUN; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSCRIPTION FACTOR AP 1; UROKINASE;

ARTICLE; CELL ADHESION; CELL ASSAY; CELL INVASION; CELL MIGRATION; CELL STRAIN HEPG2; CELL VIABILITY; CONTROLLED STUDY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME SYNTHESIS; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; INHIBITION KINETICS; LIVER CANCER; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ZYMOGRAPHY;

EID: 73849121540     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2009.00540.x     Document Type: Article

References (36)

1. Weinberg AG, Finegold MJ. Primary hepatic tumors of childhood. Pathology 1983; 14: 512-37.
2. Hsiao CC, Chuang JH, Tiao MM et al. Patterns of hepatoblastoma and hepatocellular carcinoma in children after universal hepatitis B vaccination in Taiwan: a report from a single institution in southern Taiwan. J Pediatr Hematol Oncol 2009; 31: 91-6.
3. Meyers RL, Katzenstein HM, Krailo M et al. Surgical resection of pulmonary metastatic lesions in children with hepatoblastoma. J Pediatr Surg 2007; 42: 2050-6.
4. Blum HE. Hepatocellular carcinoma: therapy and prevention. World J Gastroenterol 2005; 11: 7391-400.
5. Surh YJ. Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 2003; 3: 768-80.
6. Wang YC, Huang TL. Screening of anti-Helicobacter pylori herbs deriving from Taiwanese folk medicinal plants. FEMS Immunol Med Microbiol 2005; 43: 295-300.
7. Wang YC, Huang TL. Anti-Helicobacter pylori activity of Plumbago zeylanica L. FEMS Immunol Med Microbiol 2005; 43: 407-12.
8. Dai Y, Hou LF, Chan YP et al. Inhibition of immediate allergic reactions by ethanol extract from Plumbago zeylanica stems. Biol Pharm Bull 2004; 27: 429-32.
9. Chan-Bacab MJ, Pena-Rodriguez LM. Plant natural products with leishmanicidal activity. Nat Prod Rep 2001; 18: 674-88.
10. Krishnaswamy M, Purushothaman KK. Plumbagin: a study of its anticancer, antibacterial & antifungal properties. Indian J Exp Biol 1980; 18: 876-7.
11. Sharma I, Gusain D, Dixit VP. Hypolipidaemic and antiatherosclerotic effects of plumbagin in rabbits. Indian J Physiol Pharmacol 1991; 35: 10-14.
12. Acharya BR, Bhattacharyya B, Chakrabarti G. The natural naphthoquinone plumbagin exhibits antiproliferative activity and disrupts the microtubule network through tubulin binding. Biochemistry 2008; 47: 7838-45.
13. Powolny AA, Singh SV. Plumbagin-induced apoptosis in human prostate cancer cells is associated with modulation of cellular redox status and generation of reactive oxygen species. Pharm Res 2008; 25: 2171-80.
14. Bernhard EJ, Gruber SB, Muschel RJ. Direct evidence linking expression of matrix metalloproteinase 9 (92-kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells. Proc Natl Acad Sci USA 1994; 91: 4293-7.
15. Mazar AP, Henkin J, Goldfarb RH. The urokinase plasminogen activator system in cancer: implications for tumor angiogenesis and metastasis. Angiogenesis 1999; 3: 15-32.
16. Stephens RW, Pöllänen J, Tapiovaara H et al. Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants. J Cell Biol 1989; 108: 1987-95.
17. Nagase H. Activation mechanisms and cellular metalloproteinases. Biol Chem 1997; 378: 151-60.
18. Westermarck J, Kahari VM. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 1999; 13: 781-92.
19. Sliva D. Signaling pathways responsible for cancer cell invasion as targets for cancer therapy. Curr Cancer Drug Targets 2004; 4: 327-36.
20. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem 1999; 274: 21491-4.
21. Lee SO, Jeong YJ, Im HG et al. Silibinin suppresses PMAinduced MMP-9 expression by blocking the AP-1 activation via MAPK signaling pathways in MCF-7 human breast carcinoma cells. Biochem Biophys Res Commun 2007; 354: 165-71.
22. Peng PL, Hsieh YS, Wang CJ et al. Inhibitory effect of berberine on the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2. Toxicol Appl Pharmacol 2006; 214: 8-15.
23. Mossa JS, El-Feraly FS, Muhammad I. Antimycobacterial constituents from Juniperus procera, Ferula communis and Plumbago zeylanica and their in vitro synergistic activity with isonicotinic acid hydrazide. Phytother Res 2004; 18: 934-7.
24. Srinivas P, Gopinath G, Banerji A et al. Plumbagin induces reactive oxygen species, which mediate apoptosis in human cervical cancer cells. Mol Carcinog 2004; 40: 201-11.
25. Hsieh YJ, Lin LC, Tsai TH. Determination and identification of plumbagin from the roots of Plumbago zeylanica L. by liquid chromatography with tandem mass spectrometry. J Chromatogr A 2005; 1083: 41-5.
26. Ding Y, Chen ZJ, Liu S et al. Inhibition of Nox-4 activity by plumbagin, a plant-derived bioactive naphthoquinone. J Pharm Pharmacol 2005; 57: 111-16.
27. Kleiner DE, Stetler-Stevenson WG. Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol 1999; 43 (Suppl.): S42-51.
28. Chen PN, Hsieh YS, Chiou HL et al. Silibinin inhibits cell invasion through inactivation of both PI3K-Akt and MAPK signaling pathways. Chem Biol Interact 2005; 156: 141-150.
29. Lee SJ, Park SS, Lee US et al. Signaling pathway for TNF-alpha-induced MMP-9 expression: mediation through p38 MAP kinase, and inhibition by anti-cancer molecule magnolol in human urinary bladder cancer 5637 cells. Int Immunopharmacol 2008; 8: 1821-6.
30. Geletu G, Plamadeala P, Gogalniceanu D et al. Urokinase-type plasminogen activator (uPA) and its inhibitor-new prognostic factors in oral squamous cell carcinoma. Rev Med Chir Soc Med Nat Iasi 2004; 108: 79-84.
31. Kurahara S, Shinohara M, Ikebe T et al. Expression of MMPS, MT-MMP, and TIMPs in squamous cell carcinoma of the oral cavity: correlations with tumor invasion and metastasis. Head Neck 1999; 21: 627-38.
32. Wei Y, Lukashev M, Simon DI. Regulation of integrin function by the urokinase receptor. Science 1996; 80: 529-37.
33. Jiang Y, Goldberg ID, Shi YE. Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 2002; 21: 2245-52.
34. Liu JR, Yang BF, Chen BQ et al. Inhibition of beta-ionone on SGC-7901 cell proliferation and upregulation of metalloproteinases-1 and -2 expression. World J Gastroenterol 2004; 10: 167-71.
35. Shao ZM, Wu J, Shen ZZ et al. Genistein inhibits both constitutive and EGF-stimulated invasion in ER-negative human breast carcinoma cell lines. Anticancer Res 1998; 18: 1435-9.
36. Cha HJ, Bae SK, Lee HY et al. Anti-invasive activity of ursolic acid correlates with the reduced expression of matrix metalloproteinase-9 (MMP-9) in HT1080 human fibrosarcoma cells. Cancer Res 1996; 56: 2281-4.